Testimonials from Colleagues*

You will need Adobe^® Flash Player.

Dr. James Byrne, is a maternal and fetal medicine specialist at Santa Clara Valley Medical Center in Saratoga, California.

Nancy Jo Reedy, is a certified nurse midwife at Andrew's Women's Hospital in Fort Worth, TX.

Kathryn Shaw, MD, a perinatologist at White Memorial Medical Center in Los Angeles, finds FullTerm, The Fetal Fibronectin Test, to be "far superior" to other methods of assessing the risk of preterm delivery. Says Dr. Shaw:

Gary Joffe, MD, a perinatologist in Albuquerque, New Mexico, administers FullTerm, The Fetal Fibronectin Test, primarily to patients with symptoms of preterm labor, but also tests asymptomatic women with a history of preterm birth (PTB) or other risk factors for PTB. Dr. Joffe finds FullTerm, The Fetal Fibronectin Test, to be the "best predictor" of PTB.

Thomas A. Raskauskas, MD, of the North Shore Medical Center in Salem, Massachusetts, finds FullTerm, The Fetal Fibronectin Test, to be "the best method to date" for assessing preterm delivery risk. He tests asymptomatic women with a history of preterm birth or other risk factors for PTB. Dr. Raskauskas recounts the following anecdote regarding FullTerm, The Fetal Fibronectin Test:

John M. Thorp, Jr, MD, is a perinatologist and professor of obstetrics and gynecology at the University of North Carolina School of Medicine. The majority of his patients are high risk. Dr. Thorp relies on the high negative predictive value of FullTerm, The Fetal Fibronectin Test, to avoid unnecessary treatment of preterm labor symptoms. He finds the test to be "superior to clinical judgment."

Dr. Thorp recalls a patient who was reluctant to become pregnant again due to preterm uterine activity in a previous pregnancy, and who did not want to be "sentenced" to bed rest again. He says:

Daniel Eller, MD, uses FullTerm, The Fetal Fibronectin Test, in his urban, maternal-fetal medicine practice in Atlanta, Georgia. He tests hospitalized patients with shortened cervices or symptoms of preterm labor and outpatients with shortened cervices or other risk factors for PTD. FullTerm, The Fetal Fibronectin Test, helps him determine which patients need to be hospitalized and for how long. He says that a negative test result allows him to be less aggressive with tocolytics and hospitalization than he otherwise would be.

Dr. Eller's patients reap the benefits of FullTerm, The Fetal Fibronectin Test, when they avoid weeks or even months of hospitalization by virtue of testing negative. Of one patient in particular, he says

*The views expressed in these testimonials are the opinions of physicians, and are not necessarily the opinions of Hologic, Inc., its officers, directors, and employees.